Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...